Literature DB >> 16175052

Chemopreventive effects of various concentrations of alpha-santalol on skin cancer development in CD-1 mice.

C Dwivedi1, E R Maydew, J J Hora, D M Ramaeker, Xiangming Guan.   

Abstract

Previous studies from this laboratory have indicated that alpha-santalol (5%) provides chemopreventive effects in 7,12-dimethylbenz[a]anthracene (DMBA)-initiated and 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted skin cancer in CD-1 and SENCAR mice. Skin cancer development is associated with increased ornithine decarboxylase (ODC) activity, DNA synthesis and rapid proliferation of epidermal cells. The purpose of this investigation was to determine the effects of various concentrations (1.25% and 2.5%) of alpha-santalol on DMBA-initiated and TPA-promoted skin cancer development, TPA-induced ODC activity, and DNA synthesis in CD-1 mice. alpha-Santalol treatment at both concentrations (1.25% and 2.5%) prevented the skin cancer development. alpha-Santalol treatment (1.25% and 2.5%) resulted in a significant decrease in the TPA-induced ODC activity and incorporation of [3H]thymidine in DNA in the epidermis of CD-1 mice. There was no significant difference in the effects of 1.25% and 2.5% alpha-santalol on tumour incidence, multiplicity, epidermal TPA-induced ODC activity, or DNA synthesis in CD-1 mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16175052     DOI: 10.1097/01.cej.0000178075.20124.2a

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  8 in total

1.  Topical application of a sandal wood oil and turmeric based cream prevents radiodermatitis in head and neck cancer patients undergoing external beam radiotherapy: a pilot study.

Authors:  P L Palatty; A Azmidah; S Rao; D Jayachander; K R Thilakchand; M P Rai; R Haniadka; P Simon; R Ravi; R Jimmy; P F D'souza; R Fayad; M S Baliga
Journal:  Br J Radiol       Date:  2014-04-02       Impact factor: 3.039

2.  Weight Loss via exercise with controlled dietary intake may affect phospholipid profile for cancer prevention in murine skin tissues.

Authors:  Ping Ouyang; Yu Jiang; Hieu M Doan; Linglin Xie; David Vasquez; Ruth Welti; Xiaoyu Su; Nanyan Lu; Betty Herndon; Shie-Shien Yang; Richard Jeannotte; Weiqun Wang
Journal:  Cancer Prev Res (Phila)       Date:  2010-03-16

3.  Chemoprevention of Breast Cancer by Transdermal Delivery of α-Santalol through Breast Skin and Mammary Papilla (Nipple).

Authors:  Kaushalkumar Dave; Fahd M Alsharif; Saiful Islam; Chandradhar Dwivedi; Omathanu Perumal
Journal:  Pharm Res       Date:  2017-06-06       Impact factor: 4.200

Review 4.  Novel investigational drugs for basal cell carcinoma.

Authors:  Po-Lin So; Jean Y Tang; Ervin H Epstein
Journal:  Expert Opin Investig Drugs       Date:  2010-09       Impact factor: 6.206

5.  Effects of magnolol on UVB-induced skin cancer development in mice and its possible mechanism of action.

Authors:  Chandeshwari Chilampalli; Ruth Guillermo; Xiaoying Zhang; Radhey S Kaushik; Alan Young; David Zeman; Michael B Hildreth; Hesham Fahmy; Chandradhar Dwivedi
Journal:  BMC Cancer       Date:  2011-10-20       Impact factor: 4.430

6.  Functional Characterization of Novel Sesquiterpene Synthases from Indian Sandalwood, Santalum album.

Authors:  Prabhakar Lal Srivastava; Pankaj P Daramwar; Ramakrishnan Krithika; Avinash Pandreka; S Shiva Shankar; Hirekodathakallu V Thulasiram
Journal:  Sci Rep       Date:  2015-05-15       Impact factor: 4.379

7.  East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease.

Authors:  Manju Sharma; Corey Levenson; John C Browning; Emily M Becker; Ian Clements; Paul Castella; Michael E Cox
Journal:  Front Pharmacol       Date:  2018-03-09       Impact factor: 5.810

8.  Molecular conformation changes along the malignancy revealed by optical nanosensors.

Authors:  Simona Cinta Pinzaru; Alexandra Falamas; Cristina Adriana Dehelean
Journal:  J Cell Mol Med       Date:  2013-01-10       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.